The first oncogenic role of RET was described in the most common endocrine cancer, papillary thyroid carcinoma (PTC) [4], as the result of genomic rearrangements leading to its constitutive activation and to increased cell survival, proliferation and motility [5]. Here, RET is linked to differentiated thyroid carcinoma.